Toxicity and Patient-Reported Outcomes of a Phase 2 Randomized Trial of Prostate and Pelvic Lymph Node Versus Prostate only Radiotherapy in Advanced Localised Prostate Cancer (PIVOTAL)

Published on Mar 1, 2019in International Journal of Radiation Oncology Biology Physics5.859
· DOI :10.1016/J.IJROBP.2018.10.003
David P. Dearnaley108
Estimated H-index: 108
(ICR: Institute of Cancer Research),
Clare Griffin15
Estimated H-index: 15
(ICR: Institute of Cancer Research)
+ 15 AuthorsEmma Hall57
Estimated H-index: 57
(ICR: Institute of Cancer Research)
Sources
Abstract
Purpose To establish the toxicity profile of high-dose pelvic lymph node intensity-modulated radiation therapy (IMRT) and to assess whether it is safely deliverable at multiple centers. Methods and Materials In this phase 2 noncomparative multicenter trial, 124 patients with locally advanced, high-risk prostate cancer were randomized between prostate-only IMRT (PO) (74 Gy/37 fractions) and prostate and pelvic lymph node IMRT (PP 74 Gy/37 fractions to prostate, 60 Gy/37 fractions to pelvis). The primary endpoint was acute lower gastrointestinal (GI) Radiation Therapy Oncology Group (RTOG) toxicity at week 18, aiming to exclude a grade 2 or greater (G2+) toxicity-free rate of 80% in the PP 90% confidence interval [CI], 90.0-99.4) for the PO group and 59 of 62 (95.2%; 90% CI, 88.0-98.7) for the PP in addition, RTOG G2+ bladder toxicity was 5.1% (95% CI, 1.7%-14.9%) for the PO group and 5.6% (95% CI, 1.8%-16.7%) for the P&P group. Conclusions PIVOTAL demonstrated that high-dose pelvic lymph node IMRT can be delivered at multiple centers with a modest side effect profile. Although safety data from the present study are encouraging, the impact of P&P IMRT on disease control remains to be established.
Download
📖 Papers frequently viewed together
55 Citations
56 Citations
References26
Newest
#1Mack Roach (UCSF: University of California, San Francisco)H-Index: 88
#2Jennifer Moughan (American College of Radiology)H-Index: 32
Last. Howard M. Sandler (Cedars-Sinai Medical Center)H-Index: 96
view all 23 authors...
Summary Background The NRG/RTOG 9413 study showed that whole pelvic radiotherapy (WPRT) plus neoadjuvant hormonal therapy (NHT) improved progression-free survival in patients with intermediate-risk or high-risk localised prostate cancer compared with prostate only radiotherapy (PORT) plus NHT, WPRT plus adjuvant hormonal therapy (AHT), and PORT plus AHT. We provide a long-term update after 10 years of follow-up of the primary endpoint (progression-free survival) and report on the late toxicities...
80 CitationsSource
Purpose To investigate the feasibility of dose escalation and hypofractionation of pelvic lymph node intensity modulated radiation therapy (PLN-IMRT) in prostate cancer (PCa). Methods and Materials In a phase 1/2 study, patients with advanced localized PCa were sequentially treated with 70 to 74 Gy to the prostate and dose-escalating PLN-IMRT at doses of 50 Gy (cohort 1), 55 Gy (cohort 2), and 60 Gy (cohort 3) in 35 to 37 fractions. Two hypofractionated cohorts received 60 Gy to the prostate and...
20 CitationsSource
#1Patricia Holch (LBU: Leeds Beckett University)H-Index: 13
#2Ann Henry (University of Leeds)H-Index: 32
Last. Galina Velikova (University of Leeds)H-Index: 62
view all 10 authors...
Purpose This review aimed to determine the clinician and patient reported outcome (PRO) instruments currently usedin randomized controlled trials (RCTs) of radical radiation therapy for nonmetastatic prostate cancer to report acute and late adverse events (AEs), review the quality of methodology and PRO reporting, and report the prevalence of acute and late AEs. Methods and Materials The MEDLINE, EMBASE, and Cochrane databases were searched between April and August 2014 according to the Preferre...
10 CitationsSource
#1David P. Dearnaley (ICR: Institute of Cancer Research)H-Index: 108
#2Isabel Syndikus (Clatterbridge Cancer Centre NHS Foundation Trust)H-Index: 27
Last. Emma Hall (ICR: Institute of Cancer Research)H-Index: 57
view all 29 authors...
Summary Background Prostate cancer might have high radiation-fraction sensitivity that would give a therapeutic advantage to hypofractionated treatment. We present a pre-planned analysis of the efficacy and side-effects of a randomised trial comparing conventional and hypofractionated radiotherapy after 5 years follow-up. Methods CHHiP is a randomised, phase 3, non-inferiority trial that recruited men with localised prostate cancer (pT1b–T3aN0M0). Patients were randomly assigned (1:1:1) to conve...
549 CitationsSource
#1Juanita Crook (UBC: University of British Columbia)H-Index: 16
Elective pelvic nodal irradiation (EPNI) remains a controversial area in prostate cancer management. Two articles published in the International Journal of Radiation, Oncology, Biology and Physics present additional data regarding the benefits of EPNI for patients with high-risk prostate cancer, suggesting that EPNI confers no benefit in overall survival or biochemical-progression-free survival.
4 CitationsSource
#1Arya Amini (University of Colorado Denver)H-Index: 22
#2Bernard L. Jones (University of Colorado Denver)H-Index: 23
Last. Brian D. Kavanagh (University of Colorado Denver)H-Index: 66
view all 6 authors...
Purpose/Objectives The addition of whole pelvic (WP) compared with prostate-only (PO) radiation therapy (RT) for clinically node-negative prostate cancer remains controversial. The purpose of our study was to evaluate the survival benefit of adding WPRT versus PO-RT for high-risk, node-negative prostate cancer, using the National Cancer Data Base (NCDB). Methods and Materials Patients with high-risk prostate cancer treated from 2004 to 2006, with available data for RT volume, coded as prostate a...
23 CitationsSource
#1V. HarrisH-Index: 7
#2John Staffurth (Cardiff University)H-Index: 34
Last. David P. DearnaleyH-Index: 108
view all 16 authors...
Purpose The purpose of this study was to establish reproducible guidelines for delineating the clinical target volume (CTV) of the pelvic lymph nodes (LN) by combining the freehand Royal Marsden Hospital (RMH) and Radiation Therapy Oncology Group (RTOG) vascular expansion techniques. Methods and Materials Seven patients with prostate cancer underwent standard planning computed tomography scanning. Four different CTVs (RMH, RTOG, modified RTOG, and Prostate and pelvIs Versus prOsTate Alone treatm...
53 CitationsSource
#1David P. Dearnaley (ICR: Institute of Cancer Research)H-Index: 108
#2Isabel SyndikusH-Index: 27
Last. Emma Hall (ICR: Institute of Cancer Research)H-Index: 57
view all 22 authors...
Summary Background Prostate cancer might have high radiation-fraction sensitivity, implying a therapeutic advantage of hypofractionated treatment. We present a pre-planned preliminary safety analysis of side-effects in stages 1 and 2 of a randomised trial comparing standard and hypofractionated radiotherapy. Methods We did a multicentre, randomised study and recruited men with localised prostate cancer between Oct 18, 2002, and Aug 12, 2006, at 11 UK centres. Patients were randomly assigned in a...
245 CitationsSource
#1Padraig WardeH-Index: 79
#2Malcolm David Mason (Cardiff University)H-Index: 91
Last. Wendy R. ParulekarH-Index: 33
view all 19 authors...
Summary Background Whether the addition of radiation therapy (RT) improves overall survival in men with locally advanced prostate cancer managed with androgen deprivation therapy (ADT) is unclear. Our aim was to compare outcomes in such patients with locally advanced prostate cancer. Methods Patients with: locally advanced (T3 or T4) prostate cancer (n=1057); or organ-confined disease (T2) with either a prostate-specific antigen (PSA) concentration more than 40 ng/mL (n=119) or PSA concentration...
434 CitationsSource
#1T. Guerrero Urbano (The Royal Marsden NHS Foundation Trust)H-Index: 7
#2Vincent Khoo (The Royal Marsden NHS Foundation Trust)H-Index: 62
Last. David P. Dearnaley (The Royal Marsden NHS Foundation Trust)H-Index: 108
view all 17 authors...
Abstract Aim Pelvic irradiation in addition to prostate irradiation may improve outcome in locally advanced prostate cancer, but is associated with dose-limiting bowel toxicity. We report the preliminary results of a dose escalation study using intensity-modulated radiotherapy. Materials and methods Eligible patients had high-risk (T3, Gleason ≥8 or prostate-specific antigen ≥20ng/ml) or lymph node-positive disease. Intensity-modulated radiotherapy was inverse planned giving 70Gy/35 fractions to...
36 CitationsSource
Cited By19
Newest
#1Stine E. Petersen (Aarhus University Hospital)H-Index: 7
#2Lise Bech Jellesmark Thorsen (Aarhus University Hospital)H-Index: 4
Last. Lise Bentzen (Aarhus University Hospital)H-Index: 19
view all 10 authors...
BACKGROUND The aim of this study was to assess acute and late morbidity measured by the physician and patient-reported outcomes (PROs) in high-risk prostate cancer (PC) patients receiving whole pelvic intensity-modulated radiotherapy (IMRT) in the setting of a national clinical trial. MATERIAL AND METHODS A total of 88 patients with adenocarcinoma of the prostate and high-risk parameters were enrolled from 2011 to 2013. All patients received 78 Gy in 39 fractions of IMRT delivering simultaneous ...
Source
#2S.G. JhavarH-Index: 2
view all 5 authors...
Source
#1Rihito Aizawa (Kyoto University)H-Index: 4
#2Kiyonao Nakamura (Kyoto University)H-Index: 6
Last. Takashi Mizowaki (Kyoto University)H-Index: 32
view all 10 authors...
The aim of this study was to evaluate the long-term efficacy and safety of whole pelvic intensity-modulated radiation therapy with a simultaneous-integrated boost (WP-SIB-IMRT) for locally advanced prostate cancer (LAPCa). All patients with cT3–4N0M0 prostate cancer treated with WP-SIB-IMRT between February 2006 and September 2009 at our institution were analyzed retrospectively. The prescribed dose was 78 Gy to the prostate and 58.5 Gy to the prophylactic pelvic lymph nodal area in 39 fractions...
1 CitationsSource
#1Gert De Meerleer (Katholieke Universiteit Leuven)H-Index: 36
#2Charlien Berghen (Katholieke Universiteit Leuven)H-Index: 6
Last. Kato Rans (Katholieke Universiteit Leuven)H-Index: 2
view all 13 authors...
In patients with prostate cancer who have a high risk of pelvic nodal disease, the use of elective whole pelvis radiotherapy is still controversial. Two large, randomised, controlled trials (RTOG 9413 and GETUG-01) did not show a benefit of elective whole pelvis radiotherapy over prostate-only radiotherapy. In 2020, the POP-RT trial established the role of elective whole pelvis radiotherapy in patients who have more than a 35% risk of lymph node invasion (known as the Roach formula). POP-RT stre...
Source
Source
#1P. Turner ('QUB': Queen's University Belfast)H-Index: 2
#2Suneil Jain ('QUB': Queen's University Belfast)H-Index: 28
Last. Joe M. O'Sullivan ('QUB': Queen's University Belfast)H-Index: 53
view all 10 authors...
Purpose: null Radium-223 is an alpha-emitting radionuclide associated with overall survival (OS) improvement in metastatic castration-resistant prostate cancer (mCRPC). External beam radiotherapy (EBRT) to prostate extends OS in men with metastatic hormone-sensitive prostate cancer (mHSPC) limited to less than 4 metastases. We hypothesized that combination radium-223 + pelvic EBRT could safely deliver maximal radiotherapy doses to primary and metastatic prostate cancer and may improve disease co...
1 CitationsSource
#1William A. Hall (MCW: Medical College of Wisconsin)H-Index: 23
#2Meena Bedi (MCW: Medical College of Wisconsin)H-Index: 10
Last. Colleen A. Lawton (MCW: Medical College of Wisconsin)H-Index: 61
view all 13 authors...
Purpose/Objectives There remains limited data as to the feasibility, safety and efficacy of higher doses of elective radiation therapy (RT) to the pelvic lymph nodes in men with high risk prostate cancer. We conducted a phase II study to evaluate moderate dose escalation to the pelvic lymph nodes using a simultaneous integrated boost (SIB) to the prostate. Materials/Methods Patients were eligible with biopsy proven adenocarcinoma of the prostate, a calculated lymph node (LN) risk of at least 25%...
Source
Radiotherapy (RT) target volume concepts for locally advanced lung cancer have been under discussion for years. Although they may be as important as treatment doses, many aspects of them are still based on conventions, which, due to the paucity of prospective data, rely on long-term practice or on clinical knowledge and experience (e.g., on patterns of spread or recurrence). However, in recent years, large improvements have been made in medical imaging and molecular imaging methods have been imp...
1 CitationsSource
#1Robert FoersterH-Index: 9
#2Daniel R. ZwahlenH-Index: 18
Last. Tejshri Telkhade (HBNI: Homi Bhabha National Institute)H-Index: 1
view all 15 authors...
Background: Radiotherapy (RT) is an established, potentially curative treatment option for all risk constellations of localized prostate cancer (PCA). Androgen deprivation therapy (ADT) and dose-escalated RT can further improve outcome in high-risk (HR) PCA. In recent years, shorter RT schedules based on hypofractionated RT have shown equal outcome. Stereotactic body radiotherapy (SBRT) is a highly conformal RT technique enabling ultra-hypofractionation which has been shown to be safe and effici...
4 CitationsSource
•PIVOTALboost evaluates benefits/toxicity of pelvic node RT and focal boost dose escalation.•Unfavourable intermediate/high risk and bulky local disease are most likely to benefit.•Functional MRI imaging is used to select patients for different types of dose escalation.•HDR brachytherapy or focal dose escalation with IMRT are used as options.•Training and support is provided to reduce variations of contouring and radiotherapy planning.•The trial is recruiting patients in 38 radiotherapy centres ...
7 CitationsSource